How is the standard dose of trametinib specified?

Trametinib is a MEK inhibitor that is commonly used to treat BRAF mutation-positive melanoma, non-small cell lung cancer, and thyroid cancer. The dosage and administration of trametinib need to be adjusted based on the patient's specific condition and treatment response. Based on the drug's use guidelines and clinical practice, the standard recommended dose for adult patients is usually 2 mg orally once daily.

Patients should take trametinib at a fixed time every day to ensure a stable concentration of the drug in the body. It is recommended that patients take trametinib at least 1 hour before meals or at least 2 hours after meals to maximize the absorption of the drug and reduce gastrointestinal discomfort symptoms. Patients need to regularly monitor important indicators such as liver function and heart function while taking the drug, especially at the beginning of treatment, because trametinib may cause hepatotoxicity and cardiovascular side effects, such as bradycardia and QT interval prolongation.

For pediatric patients, the recommended dose of trametinib is adjusted based on body weight, and the dose is usually customized by doctors based on specific treatment needs. Dose adjustment is particularly important in pediatric patients because children metabolize drugs at different rates than adults and may require more refined dose adjustments.

When treated with trametinib, patients also need to regularly check their condition to ensure the effectiveness of the drug and adjust the dosage to cope with possible side effects. Patients should follow their doctor's advice and not adjust dosage or stop treatment on their own. The duration of trametinib treatment is usually determined based on the patient's clinical response and tolerability.

In general, the standard dose of trametinib is 2mg per day for adults, and is adjusted according to body weight for pediatric patients. Patients should strictly follow medical instructions during treatment and regularly check relevant indicators to ensure the safety and effectiveness of the drug.

Reference materials:https://go.drugbank.com/drugs/DB08911